Clinical significance of AGE-RAGE axis in colorectal cancer: Associations with glyoxalase-I, adiponectin receptor expression and prognosis

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Sakellariou, Stratigoula ^a   Fragkou, Paraskevi ^a   Levidou, Georgia ^a   Gargalionis, Antonios N ^a   Piperi, Christina ^a   Dalagiorgou, Georgia ^a   Adamopoulos, Christos ^a   Saetta, Angelica ^a   Agrogiannis, George ^a   Theohari, Irini ^a   Sougioultzis, Stavros ^a   Tsioli, Panagiota ^a   Karavokyros, Ioannis ^a   Tsavaris, Nikolaos ^a   Kostakis, Ioannis D ^a   Zizi Serbetzoglou, Adamantia ^b   Vandoros, Gerasimos P ^c   Patsouris, Efstratios ^a   Korkolopoulou, Penelope ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

Author keywords

Adiponectin receptor; AGE; Colorectal cancer; Glyoxalase I; RAGE

Indexed keywords

ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; LACTOYLGLUTATHIONE LYASE; TUMOR MARKER; ADIPONECTIN RECEPTOR; ADIPOR1 PROTEIN, HUMAN; ADIPOR2 PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; AGED; ANTIBODY LABELING; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COHORT ANALYSIS; COLLOID CARCINOMA; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURVIVAL ANALYSIS; SURVIVAL TIME; WESTERN BLOTTING; COLORECTAL NEOPLASMS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LACTOYLGLUTATHIONE LYASE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ADIPONECTIN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84978656574     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2213-5     Document Type: Article

References (42)

1. Binefa G, Rodríguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20:6786-808.
2. Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: associations, mechanisms, and implications for medical practice. World J Diabetes. 2014;5:372-80. doi: 10.4239/wjd.v5.i3.372.
3. Prasad C, Imrhan V, Marotta F, Juma S, Vijayagopal P. Lifestyle and advanced glycation End products (AGEs) burden: its relevance to healthy aging. Aging Dis. 2014;5:212-7. doi: 10.14336/AD.2014.0500212.
4. Peppa M, Uribarri J, Vlassara H. Aging and glycoxidant stress. Hormones. 2008;7:123-32.
5. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, Kandaraki E, Levidou G, Papalois A, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med. 2007;85:1413-20.
6. Nedić O, Rattan SI, Grune T, Trougakos IP. Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology. Free Radic Res. 2013;47 Suppl 1:28-38. doi: 10.3109/10715762.
7. Kandarakis SA, Piperi C, Topouzis F, Papavassiliou AG. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog Retin Eye Res. 2014;42C:85-102. doi: 10.1016/j.preteyeres.2014.05.002.
8. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7:17. doi: 10.1186/1479-5876-7-17.
9. Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis. 2010;31:334-41. doi: 10.1093/carcin/bgp322.
10. Marinakis E, Bagkos G, Piperi C, Roussou P, Diamanti-Kandarakis E. Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention? Clin Chem Lab Med. 2014;52:189-200. doi: 10.1515/cclm-2013-0578.
11. Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch. 2005;446:411-5.
12. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer. 2003;104:722-7.
13. Kandaraki E, Chatzigeorgiou A, Piperi C, Palioura E, Palimeri S, Korkolopoulou P, et al. Reduced ovarian glyoxalase-I activity by dietary glycotoxins and androgen excess: a causative link to polycystic ovarian syndrome. Mol Med. 2012;18:1183-9. doi: 10.2119/molmed.2012.00293.
14. Thornalley PJ. Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans. 2003;31:1343-8.
15. Santarius T, Bignell GR, Greenman CD, Widaa S, Chen L, Mahoney CL, et al. GLO1-A novel amplified gene in human cancer. Genes Chromosomes Cancer. 2010;49:711-25. doi: 10.1002/gcc.20784.
16. Ranganathan S, Tew KD. Analysis of glyoxalase-I from normal and tumor tissue from human colon. Biochim Biophys Acta. 1993;1182:311-6.
17. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29:2959-71. doi: 10.1093/eurheartj/ehn387.
18. Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, et al. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res. 2009;29:3321-7.
19. Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009;20:625-33. doi: 10.1007/s10552-008-9273-z.
20. Barresi V, Grosso M, Giuffrè G, Tuccari G, Barresi G. The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clin Pathol. 2009;62:705-9. doi: 10.1136/jcp.2009.066175.
21. Gialamas SP, Petridou ET, Tseleni-Balafouta S, Spyridopoulos TN, Matsoukis IL, Kondi-Pafiti A, et al. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism. 2011;60:1530-8. doi: 10.1016/j.metabol.2011.03.020.
22. Byeon JS, Jeong JY, Kim MJ, Lee SM, Nam WH, Myung SJ, et al. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer. 2010;127:2758-67. doi: 10.1002/ijc.25301.
23. Hiyoshi M, Tsuno NH, Otani K, Kawai K, Nishikawa T, Shuno Y, et al. Adiponectin receptor 2 is negatively associated with lymph node metastasis of colorectal cancer. Oncol Lett. 2012;3(4):756-60.
24. Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A, Nifli AP, et al. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer. 2008;15:289-99. doi: 10.1677/ERC-07-0197.
25. Yamamoto N, Oshima T, Yoshihara K, Sato T, Yamada R, Fujii S, et al. Reduced expression of the AdipoR1 gene is correlated with venous invasion in colorectal cancer. Mol Med Rep. 2009;2:555-9. doi: 10.3892/mmr_00000136.
26. Tahara N, Yamagishi S, Tahara A, Ishibashi M, Hayabuchi N, Takeuchi M, et al. Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation. Int J Cardiol. 2012;158:461-2. doi: 10.1016/j.ijcard.2012.05.015.
27. Del Turco S, Navarra T, Gastaldelli A, Basta G. Protective role of adiponectin on endothelial dysfunction induced by AGEs: a clinical and experimental approach. Microvasc Res. 2011;82:73-6. doi: 10.1016/j.mvr.2011.03.003.
28. Maeda S, Matsui T, Takeuchi M, Yamagishi S. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase-mediated oxidative stress generation. Int J Cardiol. 2011;152:408-10. doi: 10.1016/j.ijcard.2011.08.043.
29. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073-87e3.
30. Zill H, Günther R, Erbersdobler HF, Fölsch UR, Faist V. RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochem Biophys Res Commun. 2001;288:1108-11.
31. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008;29:2035-43. doi: 10.1093/carcin/bgn188.
32. Hu X, Cheng Y. Possible participation of receptor for advanced glycation end products (RAGE) in the origin of cancer stem cells in diabetic patients with colon cancer. Med Hypotheses. 2013;80:620-3. doi: 10.1016/j.mehy.2013.02.004.
33. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep. 2003;10:445-8.
34. Heijmans J, Büller NV, Hoff E, Dihal AA, van der Poll T, van Zoelen MA, et al. Rage signalling promotes intestinal tumourigenesis. Oncogene. 2013;32:1202-6. doi: 10.1038/onc.2012.119.
35. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol. 2002;196:163-70.
36. Ferroni P, Palmirotta R, Spila A, Martini F, Raparelli V, Fossile E, et al. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res. 2007;27:483-9.
37. Gonullu G, Kahraman H, Bedir A, Bektas A, Yücel I. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis. 2010;25:205-12. doi: 10.1007/s00384-009-0828-6.
38. Barresi V, Tuccari G, Barresi G. Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density. Pathology. 2009;41:533-8.
39. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006;345:271-9.
40. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun. 2006;340:1158-66.
41. Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol. 2009;34:339-44.
42. Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol. 2010;24:1441-52. doi: 10.1210/me.2009-0498.